I wouldn't be surprised if additional tests are required either. Seems like the tone for the PCa test has definitely changed from very optimistic to much more negative since RP came on-board. Even as recently as a few months ago NP was complimenting RP for discussions with the test. Now, RP's employment was terminated, PCa no longer listed in the milestones on the current investor slides and a potential 2-year warning note in the 10-K.

While I was hoping this would provide enough up-front financing to stop the dilution until combo is approved, I don't think this is as likely as originally thought or advertised. The good news is (outside of financing) this has no impact on leronlimab in any indications.

As others noted, my current interpretation is this falls on RP misrepresenting it or newly discovered tests once discussion began with NanoString (as they are more versed in devices and tests).